We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





30-Second COVID-19 Breathalyzer Test Could Be a Game-Changer

By LabMedica International staff writers
Posted on 13 Oct 2020
India and Israel are jointly developing a new rapid COVID-19 testing kit that will simply require an individual to blow into a tube and deliver results in less than a minute, making the test a real game-changer.

Israeli Ambassador to India Ron Malka told the Indian news agency PTI that the test should be ready in “a matter of days.” In the operation dubbed “Open Skies,” inspired by the belief that the testing kit will enable the world to begin opening the skies, Israel has sent a high level research delegation to India for conducting a series of "final stages of testing" to develop the rapid COVID-19 testing kit. More...
The team of researchers has conducted trials using a large number of samples in India for four different kinds of technologies having the capabilities to rapidly detect SARS-CoV-2, namely sound waves, breathalyzers based on terahertz waves, isothermic identification and checking polyamino acids. According to Malka, each test has passed different stages of evaluation. The test would be extremely cheap to perform, as it would deliver results locally and eliminate logistics as well as the cost involved for sending samples to the laboratory. Malka said that India was likely to become the manufacturing headquarters for the new rapid test kit and experts from both the countries also planned to jointly develop COVID-19 vaccines.

"It will be good news for the entire world. Until we manage to immunize the entire population, this joint operation, which we had named 'open skies', would literally open the skies in terms of international travel and other economic activities as this can be used at airports and other places by requiring a person just to blow into a tube and the result would be available in 30-40-50 seconds," Malka told PTI.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.